HSP90B1 and plasma cell myeloma: Isoformselective inhibitors targeting Grp94 might be more effective for the cancers with high demand for proteins folding (multiple myeloma), inflammatory process (inflammatory colon carcinomas) and chronic infection (hepatocellular carcinoma) [127].